UBS Group AG Purchases 276,646 Shares of Pediatrix Medical Group, Inc. $MD

UBS Group AG grew its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 89.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 585,750 shares of the company’s stock after acquiring an additional 276,646 shares during the quarter. UBS Group AG owned about 0.68% of Pediatrix Medical Group worth $12,529,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of MD. Victory Capital Management Inc. grew its position in Pediatrix Medical Group by 30.7% in the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after purchasing an additional 968,553 shares during the period. Dimensional Fund Advisors LP raised its holdings in Pediatrix Medical Group by 2.5% during the third quarter. Dimensional Fund Advisors LP now owns 3,399,778 shares of the company’s stock worth $56,942,000 after buying an additional 81,554 shares during the last quarter. American Century Companies Inc. raised its holdings in Pediatrix Medical Group by 38.9% during the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock worth $44,940,000 after buying an additional 751,109 shares during the last quarter. Boston Partners lifted its stake in shares of Pediatrix Medical Group by 0.6% in the third quarter. Boston Partners now owns 1,427,953 shares of the company’s stock valued at $24,063,000 after buying an additional 8,335 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Pediatrix Medical Group by 55.4% in the third quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company’s stock valued at $19,150,000 after buying an additional 407,780 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pediatrix Medical Group

In related news, Director Shirley A. Weis sold 36,028 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.80% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently commented on MD. UBS Group boosted their target price on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. Truist Financial lifted their price target on Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, April 13th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on Pediatrix Medical Group in a report on Friday, February 20th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $22.50.

Pediatrix Medical Group Stock Performance

MD stock opened at $23.45 on Friday. The firm has a market cap of $1.93 billion, a PE ratio of 11.38 and a beta of 0.70. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.45. The business has a 50 day moving average of $21.49 and a 200-day moving average of $21.56. Pediatrix Medical Group, Inc. has a 12-month low of $11.84 and a 12-month high of $24.99.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $476.20 million for the quarter, compared to analyst estimates of $465.83 million. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.Pediatrix Medical Group’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company posted $0.33 earnings per share. As a group, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 2.07 earnings per share for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.